Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01564914 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
A Phase 2 study of Glioblastoma and Glioblastoma Multiforme, sponsored by Tracon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 4
- Study locations
NCT01564914: Completed Phase 2 study of Glioblastoma and Glioblastoma Multiforme, sponsored by Tracon Pharmaceuticals.
NCT01564914 is a Phase 2 study of Glioblastoma and Glioblastoma Multiforme that has completed, run by Tracon Pharmaceuticals. The registered enrollment target is 22 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01564914, a Phase 2 study of Glioblastoma and Glioblastoma Multiforme, has completed, sponsored by Tracon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent or progressive glioblastoma after prior antiangiogenic therapy (including anti-VEGF therapy)
Primary Outcome
Overall survival assessed by determination from time of informed consent on trial to the date of death of each patient enrolled in the trial
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG TRC105
Study Locations (4)
Ohio
- University of Cincinnati - Cincinnati
- University Hospitals of Cleveland - Cleveland
- Cleveland Clinic - Cleveland
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
What the finished NCT01564914 record still lists
NCT01564914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT01564914 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT01564914 about?
NCT01564914 is a clinical study titled "A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma". The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent or progressive glioblastoma after prior antiangiogenic therapy (including anti-VEGF therapy)
What is the current status of trial NCT01564914?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2012-05. Estimated completion is 2015-06.
What conditions does trial NCT01564914 study?
This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme.
What interventions are being tested in trial NCT01564914?
The interventions under investigation include: Bevacizumab (DRUG), TRC105 (DRUG).
Who is sponsoring clinical trial NCT01564914?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01564914 being conducted?
This trial has 4 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01564914's enrollment target sits among peer trials
22 144th of 199 higher than 56 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia